Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, Back D. Else L, et al. Among authors: watson v. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jun 1;878(19):1455-65. doi: 10.1016/j.jchromb.2010.03.036. Epub 2010 Apr 9. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 20427248
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.
Moltó J, Valle M, Back D, Cedeño S, Watson V, Liptrott N, Egan D, Miranda C, Barbanoj MJ, Clotet B. Moltó J, et al. Among authors: watson v. Antimicrob Agents Chemother. 2011 Jan;55(1):72-5. doi: 10.1128/AAC.00789-10. Epub 2010 Oct 11. Antimicrob Agents Chemother. 2011. PMID: 20937791 Free PMC article. Clinical Trial.
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Jackson A, Watson V, Back D, Khoo S, Liptrott N, Egan D, Gedela K, Higgs C, Abbas R, Gazzard B, Boffito M. Jackson A, et al. Among authors: watson v. J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):450-7. doi: 10.1097/QAI.0b013e3182364c67. J Acquir Immune Defic Syndr. 2011. PMID: 21926632 Free PMC article. Clinical Trial.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M. Else LJ, et al. Among authors: watson v. Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33. doi: 10.1128/AAC.05599-11. Epub 2011 Dec 19. Antimicrob Agents Chemother. 2012. PMID: 22183172 Free PMC article. Clinical Trial.
330 results